2022 HTRS Mentored Research Award (MRA)
 for Gene Therapy in Hemophilia A

The application window for the 2022 MRA for Gene Therapy in Hemophilia A Program is closed.  

Pre-proposals for the traditional HTRS Mentored Research Award (MRA) are being accepted through Monday, August 8, 2022.

This special HTRS Mentored Research Award (MRA) for Gene Therapy in Hemophilia A Program will provide a grant for a qualified fellow or junior attending/junior faculty (MDs, DOs, MBBSs or the equivalent) pursuing clinical, translational, or basic science research projects in Gene Therapy in Hemophilia A under the guidance of an experienced mentor. 

The goals of the overall HTRS MRA Program are to:

  • Increase the number of skilled physician-scientists in the U.S. medical workforce dedicated to long-term research careers in benign hematology
  • Support innovative research by pairing talented young physician-scientists with experienced mentors, many of whom are recognized leaders in U.S. clinical and/or basic science research in hemostasis and thrombosis
  • Provide trainees and junior faculty an accessible “on-ramp” into the NIH research pipeline by funding initial research programs that can spark and support K-award applications

2022 HTRS MRA for Gene Therapy in Hemophilia A:  Request for Proposals (RFP)

Revised Budget  Form for this MRA - Updated 12.15.2021

All applications are submitted on the  HTRS grant application site at https://htrs.smapply.org  Applicants who have not applied for an HTRS awards on Survey Monkey Apply previously should click on "Register" and create a new account with an email and password. The site allows you to save your work and return to it later.

Questions? Please contact Jennifer Ziegler, Director, Award Programs & Career Development at [email protected]


2022 HTRS Mentored Research Award for Gene Therapy in Hemophilia A

    Supported by an independent medical training grant from: